Skip to content
Sign in
In depthStableHealthFirst published 2026-11-19 23:00

Johnson & Johnson files FDA application for CAPLYTA in bipolar mania

The submission seeks approval for adults with manic or mixed episodes linked to bipolar I disorder, an indication the medicine does not currently have. The company points to two Phase 3 studies, in which symptoms improved relative to placebo and the main measures favored treatment at the end of three weeks.

42 mg

The studies compared once-daily CAPLYTA at this dose with placebo in adults with bipolar I manic episodes.1

Week 3

The company reported improvement in manic symptoms through the end of the studies' stated treatment period.1

11 million

Johnson & Johnson estimates that this many U.S. adults experience bipolar disorder during their lifetimes.1

Story

What the CAPLYTA filing seeks and what the studies reported

1 1 1 1

1 1 1 1

1 1 1 1

1 1 1 1 1

1 1 1 1

1 1 1 1

1 1 1 1

234 2 2 2

3 3 4 4 1234

Structure

Who is connected to whom
  1. 1Johnson & Johnson
  2. acquires →Fact
  3. invests in →Fact
  4. price exposure →Fact
    4ChinaGeography
  5. operates in →Fact
    5healthcareIndustry
  6. cost exposure →Fact

Impact

Spreading outward, level by level
  1. Level 1Regulatory status

    The submission seeks a new indication; CAPLYTA is not currently approved for bipolar I manic or mixed episodes.1

    Fact
  2. Level 2Evidence submitted

    The company says two pivotal Phase 3 studies supported the application and met their primary and key secondary endpoints.1

    Fact
  3. Level 3Potential adult use

    If FDA approval is granted, the requested indication would become a fifth approved adult use, according to the company.1

    Fact
  4. Level 4People with acute mania

    The filing could matter to treatment options for adults with the specified bipolar I episodes, but the application itself does not establish that the new use is approved.

    Analysis

Sources

What each source supports
1
PR Newswire news releases
2026-11-19 13:01
Original ↗
Supports 17 points
Citing: Johnson & Johnson, U.S. Food and Drug Administration, John C. Reed
2
BioPharma Dive
2026-11-16 16:57
Original ↗
Supports 2 points
Citing: Johnson & Johnson, Blackstone Life Sciences
3
Insurance Journal
2026-11-16 12:57
Original ↗
Supports 2 points
Citing: Middlesex County Superior Court
4
standard-freeholder.com
2026-11-09 17:15
Original ↗
Supports 2 points
Citing: Centers for Medicare & Medicaid Services, Johnson & Johnson, U.S. Food and Drug Administration

Written by AI from the sources listed below: every fact was checked word for word against its source, and inference is marked apart. How we write

2026-11-19 14:20 First published